The group’s principle activity is to provide catheter-based therapy for the treatment of cerebral ischemia includinng ischemic stroke. The group’s products include NeuroFlo(TM). The group operates from United States.
Executive Information
Name
Title
Email
Andrew Weiss
Dir., CEO, Pres.
N/A
Lorinda Austin
VP - Clinical Affairs
N/A
Richard Schallhorn
VP - Marketing, Research & Development, Operations
